Polish JV For USA's UniPharm Labs
UniPharm Laboratories of New Jersey, USA, has formed a joint venture,UniPharm Laboratories Polska, with the Pharmaceutical Research Institute of Poland. The US firm will have a 52.5% stake in the JV.
The company says that the JV owns the exclusive commercialization rights to PRI's products in the People's Republic of China, and will also engage in trading bulk pharmaceuticals and pharmaceutical intermediates between China and eastern Europe. In addition, the JV will conduct joint R&D programs with contributions from PRI and Beijing UniPharm Laboratories, an emerging private company in China and an affiliate of UniPharm.
Further information is available to potential parties interested in licensing and technology transfer of PRI's products from James Shen, president of UniPharm Laboratories, c/o Wicon International Ltd, 600 Sylvan Avenue, Englewood Cliffs, NJ 07632, USA. Phone: +1 201 541 8484; fax: +1 201 541 8492.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze